Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417276 | 1.00 | PIM2 (0.42) | PIM2SHMT2ROCK2ROCK1CDC42BPB | |
| SCHEMBL25290961 | 0.83 | ROCK2 (0.40) | PIM2ROCK2ROCK1CDC42BPBCHRNB2 | |
| SCHEMBL30417701 | 0.83 | ROCK2 (0.40) | PIM2ROCK2ROCK1CDC42BPBCHRNB2 | |
| SCHEMBL31145218 | 0.83 | SHMT2 (0.42) | PIM2SHMT2ROCK2ROCK1CHRNB2 | |
| SCHEMBL25292610 | 0.83 | SHMT2 (0.42) | PIM2SHMT2ROCK2ROCK1CHRNB2 | |
| SCHEMBL25292422 | 0.81 | SHMT2 (0.44) | PIM2SHMT2P2RX3P2RX2 | |
| SCHEMBL31145254 | 0.81 | SHMT2 (0.44) | PIM2SHMT2P2RX3P2RX2 | |
| SCHEMBL25293017 | 0.81 | SHMT2 (0.42) | PIM2SHMT2P2RX3P2RX2PIM3 | |
| SCHEMBL31145357 | 0.81 | SHMT2 (0.42) | PIM2SHMT2P2RX3P2RX2PIM3 | |
| SCHEMBL25251832 | 0.81 | PIM2 (0.43) | PIM2SHMT2P2RX3P2RX2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | MeiraGTx Gene Regulation Limited (GB) | 2025-03-27 | — | — | US | disclosed |
| WO-2023111686-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | MEIRAGTX UK II LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | RNGTT, SLIRP, SNRPE | PIM2 2313/4885SHMT2 964/4885ROCK2 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.